Pilot Program Surfaces Real-Time Probabilities for Clinical Trial Outcomes and Regulatory Milestones with Built-In Safeguards
Financial exchange Kalshi has partnered with public intelligence firm AppliedXL to launch a pilot suite of prediction markets focused on biotech, i.e. clinical trial outcomes and U.S. Food and Drug Administration (FDA) regulatory decisions. The initiative aims to solve biopharma’s longstanding information-silo problem by generating continuously updated, publicly accessible probabilities for drug development pipelines.
Bringing a single drug to market costs an average of $2.3 billion, according to McKinsey data, yet probability estimates have historically remained locked inside private banks, expert networks, and pharmaceutical firms. Furthermore, official reporting remains incomplete; FDA figures from April 2026 indicate that roughly 30% of trials legally required to post results had failed to do so. Kalshi’s event contracts aim to make these probabilities transparent, enabling investors, smaller developers, clinicians, and patients to track the same data.
Market Resolution Architecture and Sample Launch Contracts
To ensure market integrity and eliminate disputes, AppliedXL establishes clear resolution criteria before trading opens. Contracts resolve strictly against public artifacts—such as registered primary endpoints on ClinicalTrials.gov, official FDA approval letters, or advisory committee vote records—rather than company press releases or analyst commentary.
Pilot Safeguards and Resolution Design
The framework below outlines the resolution mechanics and pilot-specific guardrails constructed in consultation with biopharma professionals, bioethicists, and physicians:
- Late-Stage Trial Scope: Constrained to late-stage trials with publicly registered endpoints, reducing insider trading risks associated with early exploratory phases.
- Post-Enrollment Listing: Contracts open only after patient recruitment closes to prevent market prices from influencing physician referral patterns.
- Trader Verification & Compliance: Enforces mandatory employment verification alongside Kalshi’s standard prohibition on trading using material nonpublic information.
- Public Document Resolution: Settles against primary artifacts to prevent distortion from favorable corporate messaging.
Launch Contracts Available at Pilot Opening
Initial contracts deployed at launch include:
- Alzheimer’s Disease Trial: Will AR1001’s POLARIS-AD Phase 3 trial meet its primary endpoint in early Alzheimer’s disease?
- Oncology Regulatory Approval: Will the FDA approve Gilead/Arcellx’s anito-cel for relapsed/refractory multiple myeloma?
Executive Commentary: Transparency Meets Scientific Verification
Leadership from both organizations emphasized that democratizing access to clinical data helps eliminate information asymmetry in medical research.
Tarek Mansour, CEO of Kalshi, highlighted the transparency mandate:
“Drug development is one of the most important and most information-constrained industries on earth. The data that determines which drugs advance and which don’t is largely locked away from the people who need it most. Surfacing information is what Kalshi is for, and we are committed to doing it right: compliance-first, carefully scoped, and built for the long term.”
Francesco Marconi of AppliedXL addressed the technical challenge of data reconciliation:
“Clinical trial results are rarely handed to you cleanly. They come out in pieces, scattered across registries, regulatory filings, and company statements, and the press releases often put a favorable spin on what the data actually shows. Resolving a market means reconciling all of that back to the primary source, which is what we built AppliedXL to do.”
Parallel to the launch, the companies published a joint research whitepaper titled Biopharma’s Public Probability: The State and Future of Prediction Markets in Drug Development, synthesizing insights from academics, clinicians, and biopharma strategy leaders.
